• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Healthcare·4170.TWO
Share

Vectorite Biomedical Inc. Stocks

NT$ 12.15Last Updated 21.10.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

NT$ 16.47M

NT$ 12.15
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Vectorite Biomedical Inc., established in 1993 and based in New Taipei City, Taiwan, is a biotechnology firm dedicated to research and development activities globally, including a strong presence in its home country. The company's operations encompass the manufacturing of specialized cell preparation products, in addition to providing full-spectrum services for the collection, processing, and secure storage management of immune cells. These advanced cellular preparations are vital for applications in the medical fields of infectious diseases, inflammatory conditions, and various oncological and tumor-related illnesses.

Company Valuation

Undervalued
6/7

From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. Specifically, the stock is 'cheap' on P/E.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

21.10.2026 22:53

"Ambitions Greater Than Anyone Else's": JPMorgan Expects SpaceX Shares to Triple in Value

21.10.2026 22:20

Berkshire Hathaway shares hit a new record high—for the first time since Buffett announced his retirement

21.10.2026 22:08

A Left or Right Turn: What Investors Are Watching Ahead of the French Presidential Election

21.10.2026 21:10

Shares of Ray-Ban had their best day since 2008. Should you buy them?

21.10.2026 20:20

The Old World on New Chips: How Nvidia Is Driving the Industrial Revolution in Europe

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026